Ziopharm Oncology Inc. (NASDAQ:ZIOP) rose 10.5% during mid-day trading on Wednesday . The company traded as high as $5.48 and last traded at $5.37, with a volume of 3,450,867 shares. The stock had previously closed at $4.86.

ZIOP has been the topic of a number of research reports. Griffin Securities reiterated a “buy” rating and set a $21.00 target price on shares of Ziopharm Oncology in a report on Friday, July 1st. Vetr lowered shares of Ziopharm Oncology from a “strong-buy” rating to a “buy” rating and set a $9.76 target price on the stock. in a report on Monday, April 18th. Zacks Investment Research upgraded shares of Ziopharm Oncology from a “hold” rating to a “buy” rating and set a $5.50 target price on the stock in a report on Wednesday, July 27th. Raymond James Financial Inc. initiated coverage on shares of Ziopharm Oncology in a report on Thursday, June 2nd. They set a “market perform” rating on the stock. Finally, Wells Fargo & Co. upgraded shares of Ziopharm Oncology from an “underperform” rating to a “market perform” rating in a report on Wednesday. Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. Ziopharm Oncology currently has an average rating of “Buy” and a consensus price target of $9.55.

The stock’s market cap is $669.31 million. The firm’s 50 day moving average price is $5.32 and its 200 day moving average price is $6.75.

Ziopharm Oncology (NASDAQ:ZIOP) last issued its quarterly earnings results on Tuesday, August 9th. The biotechnology company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by $0.90. The firm had revenue of $1.70 million for the quarter, compared to analyst estimates of $1.52 million. Ziopharm Oncology’s quarterly revenue was up 525.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.11) EPS. Equities research analysts anticipate that Ziopharm Oncology Inc. will post ($0.42) earnings per share for the current fiscal year.

A number of large investors recently added to or reduced their stakes in the stock. Morgan Stanley increased its stake in Ziopharm Oncology by 5.1% in the fourth quarter. Morgan Stanley now owns 1,618,205 shares of the biotechnology company’s stock worth $13,447,000 after buying an additional 78,583 shares during the last quarter. California Public Employees Retirement System increased its stake in Ziopharm Oncology by 567.2% in the fourth quarter. California Public Employees Retirement System now owns 307,366 shares of the biotechnology company’s stock worth $2,554,000 after buying an additional 261,300 shares during the last quarter. Swiss National Bank increased its stake in Ziopharm Oncology by 2.2% in the fourth quarter. Swiss National Bank now owns 159,220 shares of the biotechnology company’s stock worth $1,323,000 after buying an additional 3,500 shares during the last quarter. Finally, California State Teachers Retirement System increased its stake in Ziopharm Oncology by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 212,521 shares of the biotechnology company’s stock worth $1,766,000 after buying an additional 3,354 shares during the last quarter.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.